




I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 595536104 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 26, 2005

Signature:


~~XXXXXXXXXX~~ Jie Zhou

Docket No.: 415072000101
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jennie P. MATHER et al.

Application No.: 10/672,878

Confirmation No.: 9515

Filed: September 26, 2003

Art Unit: 1644

For: COMPOSITIONS AND METHODS FOR
GENERATING MONOCLONAL
ANTIBODIES REPRESENTATIVE OF A
SPECIFIC CELL TYPE

Examiner: Y. Kim

WRITTEN ASSURANCE

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

I, Jennie P. Mather, declare as follows:

1. I am an inventor of the invention that is the subject of the above-referenced patent application (U.S. Ser. No. 10/672,878), and am familiar with the contents of the application. I am currently the founder, President and CSO of Raven biotechnologies, inc., the assignee of the above-referenced patent application.
2. I have reviewed the Office Action dated March 25, 2005 regarding this patent application. The following cells and cell lines are subject matter of this patent application: adult rat Schwann cells (ASC), embryonic rat Schwann cells (ESC), rat granulosa cell line (ROG), rat embryonic pancreatic buds epithelial cell line (BUD), rat ductal epithelial cell line (RED), non-obese diabetic mouse pancreatic ductal

Application No.: 10/672,878

2

Docket No.: 415072000101

- epithelial cell line (NODD), neonatal lung epithelial cell line (BR516), rat lung bronchiolar epithelial cell line (RL65), and rat neuroepithelial cell line (NEP).
3. These cells and cell lines are part of an existing deposit by Genentech, Inc. at the American Type Culture Collection (ATCC). The deposit of the above-listed cells and cell lines satisfies the criteria set forth in 37 CFR §§ 1.801-1.809.
 4. I am party to an Agreement effective March 1, 1999 with Genentech, Inc. where I am named as a co-depositor of these cells and cell lines at the ATCC. This Agreement grants me the right to assign my rights as co-depositor to Raven biotechnologies, inc. I have, in turn, assigned all of my rights under this Agreement to Raven biotechnologies, inc.
 5. In the event the existing deposit becomes unavailable, I assure that an acceptable deposit will be made by Raven biotechnologies, inc. on or before the payment of the issue fee for those cells and cell lines. I assure that the deposit will be made under conditions that satisfy the criteria set forth in 37 C.F.R. §§ 1.801-1.809. I also assure that Raven biotechnologies, inc. has the right to make an acceptable deposit of the above-listed cell lines.
 6. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Sept 26, 2005
(Date)

Jennie P. Mather
Jennie P. Mather, Ph.D.